WO2007017437A1 - Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol - Google Patents

Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol Download PDF

Info

Publication number
WO2007017437A1
WO2007017437A1 PCT/EP2006/064957 EP2006064957W WO2007017437A1 WO 2007017437 A1 WO2007017437 A1 WO 2007017437A1 EP 2006064957 W EP2006064957 W EP 2006064957W WO 2007017437 A1 WO2007017437 A1 WO 2007017437A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
salts
salmeterol
tiotropium
dyspnea
Prior art date
Application number
PCT/EP2006/064957
Other languages
French (fr)
Inventor
Piet Cornelissen
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to JP2008525547A priority Critical patent/JP2009504603A/en
Priority to CA002617897A priority patent/CA2617897A1/en
Priority to EP06792646A priority patent/EP1959942A1/en
Publication of WO2007017437A1 publication Critical patent/WO2007017437A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of tiotropium salts in combination with salts of salmeterol for the manufacture of a medicament for the treatment of dyspnea.
  • Medicament combinations based on anticholinergics and beta-2-agonists are known in the art.
  • the combination of long acting anticholinergics with long acting beta-2- agonists is disclosed in WO00/69468.
  • the specific combination of tiotropium salts with salts of salmeterol is also known from WO 02/38154 and WO 04/058233.
  • compositions comprising salts of tiotropium and salts of salmeterol.
  • Dyspnea is a term known in the art.
  • the term dyspnea is used to characterize a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social and environmental factors, and may induce secondary physiological and behavioural responses (see hereto: American Thoracic Society, Dyspnea: mechanisms, assessment, and management. A consensus statement, Am J Respir Crit care Med 159: 321 -340, 1999).
  • the invention relates to the use of a tiotropium salt 1 together with a salmeterol salt 2 for the manufacture of a medicament for the treatment of dyspnea.
  • the invention relates to the use of a tiotropium salt 1 for the manufacture of a salmeterol salt 2 containing medicament for the treatment of dyspnea.
  • the invention relates use of a salmeterol salt 2 for the manufacture of a tiotropium salt 1. containing medicament for the treatment of dyspnea.
  • the invention in another embodiment relates to a method for the treatment of dyspnea, comprising the administration of a therapeutically effective amount of a tiotropium salt ⁇ together with a therapeutically effective amount of a salmeterol salt 2 to a patient in need thereof.
  • therapeutically effective amount shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
  • the combined administration of a 1 and 2 may occur via a single active substance formulation but also via the successive administration of the two active substances in separate formulations. It is preferred according to the invention to administer the two active substance ingredients simultaneously in a single formulation.
  • tiotropium is intended to refer to the free cation (V) for the purposes of the present invention.
  • the tiotropium salts 1 which may be used within the scope of the present invention include the compounds which contain, in addition to the cation tiotropium V_ an anion with a single negative charge, preferably an anion selected from among chloride, bromide, iodide, methanesulphonate and para- toluenesulphonate.
  • the methanesulphonate, chloride, bromide or iodide are preferred, the methanesulphonate or bromide being of particular importance.
  • Tiotropium bromide is of exceptional importance according to the invention.
  • salts of salmeterol 2 are meant, according to the invention, pharmaceutically acceptable acid addition salts selected from among the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, xinafonic acid or maleic acid.
  • the salmeterol salts 2 selected from among hydrochloride, hydrobromide, sulphate, phosphate and xinafoate are preferred.
  • the salmeterol xinafoate salt 2 is particularly preferred.
  • the ingredients 1 and 2 may be in the form of their enantiomers, mixtures of enantiomers or in the form of the racemates.
  • the active substances 1 and 2 may optionally be in the form of the solvates or hydrates thereof.
  • Suitable inhalable preparations for the administration of 1 and 2 include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases.
  • Inhalable powders according to the invention containing the active substance combination of 1 and 2 may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable adjuvants.
  • the preparations may contain the active substance combination of ⁇ _ and 2 either together in one preparation or in two separate preparations.
  • the proportions in which the two active substances 1_ and 2 may be used in the combinations of active substances according to the invention are variable.
  • the active substances ! and 2 may optionally be in the form of the solvates or hydrates thereof.
  • the weight ratios which may be used for the purposes of the present invention vary on account of the different molecular weights of the various salt forms. Consequently, the weight ratios specified hereinafter are based on the tiotropium cation V and the free base of salmeterol 2[.
  • the combinations of active substances according to the invention may contain V_ and 2 ⁇ in weight ratios in the range from 1 :300 to 30:1 , preferably from 1 :230 to 20:1 , particularly preferably from 1 : 150 to 10: 1 , more preferably from 1 :50 to 5: 1 , particularly preferably from 1 :35 to 2:1.
  • preferred combinations of 1 and 2 according to the invention may contain tiotropium V_ and salmeterol T_ in the following weight ratios: 1 :40; 1 :20; 1 :11.1 ; 1 :10; 1 :5.6; 1 :5; 1 :2.8; 1 :2.5; 1 :1.4; 1 :1.25; 1.44:1 , 1.6:1.
  • compositions according to the invention containing the combinations of ⁇ _ and 2 are normally used so that tiotropium V_ and salmeterol 2 ⁇ are administered together in doses of 0.01 to 10000 ⁇ g, preferably 0.1 to 2000 ⁇ g, particularly preferably from 1 to 1000 ⁇ g, more preferably from 5 to 500 ⁇ g, preferably, according to the invention, from 10 to 200 ⁇ g, preferably from 20 to 100 ⁇ g, most preferably from 30 to 70 ⁇ g per single dose.
  • combinations of ⁇ _ and 2 according to the invention contain an amount of tiotropium V and salmeterol 2 ⁇ such that the total dosage per single dose is 30 ⁇ g, 35 ⁇ g, 45 ⁇ g, 55 ⁇ g, 60 ⁇ g, 65 ⁇ g, 90 ⁇ g, 105 ⁇ g, 110 ⁇ g, 110 ⁇ g, 140 ⁇ g or similar.
  • the active substances V and 21 are present in the weight rations described hereinbefore.
  • the combinations of 1 and 2 according to the invention may contain an amount of tiotropium V and salmeterol 2
  • the combinations of active substances 1 and 2 according to the invention are preferably administered by inhalation.
  • the ingredients 1 and 2 have to be incorporated in inhalable preparations.
  • Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases.
  • Inhalable powders according to the invention containing the active substance combination of 1 and 2 may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable adjuvants.
  • propellant- free solutions for inhalation also includes concentrates or sterile, ready-to-use solutions for inhalation.
  • the preparations according to the invention may contain the active substance combination of 1 and 2 either together in one preparation or in two separate preparations. These preparations which may be used within the scope of the present invention are described in detail in the following section of the specification.
  • the powders for inhalation according to the invention may contain 1 and 2 either on their own or in admixture with suitable physiologically harmless adjuvants.
  • physiologically harmless adjuvants may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these adjuvants with one another.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, saccharose, maltose
  • oligo- and polysaccharides e.g. dextranes
  • polyalcohols e.g. sorbitol, mannitol, xylitol
  • salts e.g. sodium chloride, calcium carbonate
  • Mono- or disaccharides are preferably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates, being preferred.
  • the particularly preferred adjuvant according to the invention is lactose, most preferably lactose monohydrate.
  • the adjuvants have a maximum mean particle size of up to 250 ⁇ m, preferably between 10 and 150 ⁇ m, particularly preferably between 15 and 80 ⁇ m. If desired it may be useful to add finer adjuvant fractions having a mean particle size of 1 to 9 ⁇ m to the abovementioned adjuvants. These latter finer adjuvants are also selected from the abovementioned group of adjuvants which may be used. Finally, in order to prepare the powders for inhalation according to the invention, micronised active substance 1. and 2, preferably having an average particle size of 0.5 to 10 ⁇ m, particularly preferably from 1 to 6 ⁇ m, is added to the adjuvant mixture.
  • the powders for inhalation according to the invention may be prepared and administered either in the form of a single powder mixture which contains both ⁇ _ and 2 , or in the form of separate inhalable powders which contain only 1 and 2.
  • the inhalable powders according to the invention can be administered using inhalers known from the prior art.
  • Inhalable powders according to the invention which contain a physiologically harmless adjuvant in addition to 1 and 2 may for example be administered using inhalers which meter a single dose from a reservoir by means of a measuring chamber, as described in US 4570630A, or by other devices as described in DE 36 25 685 A.
  • the inhalable powders according to the invention which contain physiologically harmless adjuvant in addition to 1 and 2 are packed into capsules (to form so-called inhalettes), which are used in inhalers such as those described, for example, in WO 94/28958.
  • lnhalable aerosols containing propellant comprising the active substance combinations of 1 and 2 according to the invention: lnhalable aerosols containing propellant according to the invention may contain 1 and 2 dissolved in the propellent gas or in dispersed form. 1 and 2 may be present in separate preparations or in a combined preparation, with ⁇ _ and 2 either both dissolved, both dispersed or only one component dissolved while the other is present in dispersed form.
  • propellent gases which can be used to prepare the inhalable aerosols according to the invention are known from the prior art.
  • Suitable propellent gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the abovementioned propellent gases may be used on their own or in mixtures thereof.
  • Particularly preferred propellent gases are halogenated alkane derivatives selected from among TG11 , TG 12, TG 134a and TG227.
  • TG134a (1 ,1 ,1 ,2-tetrafluoroethane)
  • TG227 (1 ,1 ,1 ,2,3,3,3- heptafluoropropane) and mixtures thereof are preferred according to the invention.
  • the propellant-gas-containing inhalable aerosols according to the invention may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
  • the propellant-gas-containing inhalable aerosols according to the invention may contain up to 5 % by weight of active substance 1 and/or 2. Aerosols according to the invention contain, for example, 0.002 to 5 % by weight , 0.01 to 3 % by weight , 0.015 to 2 % by weight , 0.1 to 2 % by weight , 0.5 to 2 % by weight or 0.5 to 1 % by weight of active substance ⁇ _ and/or 2.
  • the particles of active substance preferably have a mean particle size of up to 10 ⁇ m, preferably from 0.1 to 5 ⁇ m, particularly preferably from 1 to 5 ⁇ m.
  • the present invention also relates to cartridges which are fitted with a suitable valve and can be used in a suitable inhaler and which contain one of the abovementioned propellant-gas-containing inhalable aerosols according to the invention.
  • Suitable cartridges and methods of filling these cartridges with the propellant-gas-containing inhalable aerosols according to the invention are known from the prior art.
  • Suitable solvents for this include aqueous or alcoholic, preferably ethanolic solutions.
  • the solvent may be water on its own or a mixture of water and ethanol.
  • the relative proportion of ethanol to water is not restricted, but the maximum limit is preferably up to 70 percent by volume, particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remaining percent by volume are made up with water.
  • the preferred solvent is water without the addition of ethanol.
  • the solutions containing 1 and 2 separately or together, are adjusted to a pH of 2 to 7, preferably 2 to 5, particularly preferably 2.5 to 3.5, with suitable acids.
  • inhalable solutions according to the invention which contain 1 and 2 together have a pH of about 2.9.
  • This pH may be achieved using acids selected from among inorganic or organic acids.
  • inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid.
  • particularly suitable organic acids include: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid and others.
  • Preferred inorganic acids are hydrochloric acid and sulphuric acid.
  • the acids which are forming an acid addition salt with the active substance or, in the case of combined preparations, with one of the active substances are also possible.
  • organic acids ascorbic acid, fumaric acid and citric acid are preferred.
  • mixtures of the abovementioned acids may also be used, particularly in the case of acids which have properties other than their acidifying properties, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example.
  • hydrochloric acid to adjust the pH.
  • EDTA editic acid
  • sodium edetate sodium edetate
  • the content based on sodium edetate is less than 100 mg / 100 ml, preferably less than 50 mg/100 ml, most preferably less than
  • Co-solvents and/or other adjuvants may be added to the propellant-free inhalable solutions according to the invention.
  • Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropylalcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • excipients and additives is meant, in this context, any pharmacologically acceptable substance which is not an active substance, but can be formulated together with the active substance(s) in the pharmacologically suitable solvent, in order to improve the qualitative properties of the active substance formulation.
  • these substances do not have any appreciable pharmacological effects or at least have no undesirable effects in the context of the intended therapy.
  • the excipients and additives include e.g. surfactants such as e.g.
  • soya lecithin, oleic acid, sorbitan esters such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or extend the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art.
  • the additives also include pharmacologically harmless salts such as sodium chloride, for example, as isotonic agents.
  • the preferred adjuvants include antioxidants, such as ascorbic acid, for example, unless it has already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins or provitamins occurring in the human body.
  • Preservatives can be used to protect the formulation from contamination with pathogens. Suitable preservatives are those known from the prior art, particularly cetylpyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
  • the abovementioned preservatives are preferably present in concentrations of up to 50mg/100ml, particularly between 5 and 20 mg/100ml.
  • Preferred formulations contain only benzalkonium chloride and sodium edetate in addition to the solvent water and the active substance combination of 1 and 2. In another preferred embodiment, sodium edetate is omitted.
  • the propellant-free inhalable solutions according to the invention may be administered particularly using inhalers which are able to nebulise a small amount of a liquid formulation in the therapeutically necessary dose within a few seconds to form an aerosol suitable for therapeutic inhalation.
  • nebulisers are preferred in which a quantity of less than 100 ⁇ l_, preferably less than 50 ⁇ l_, particularly preferably between 20 and 30 ⁇ l_ of active substance solution can be nebulised, preferably in one operation, to produce an aerosol having an average particle size of less than 20 ⁇ m, preferably less than 10 ⁇ m, in such a way that the inhalable part of the aerosol corresponds to the therapeutically effective amount.
  • a device of this kind for the propellant-free administration of a metered amount of a liquid pharmaceutical composition for inhalation is described in detail, for example, in International Patent Application WO 91/14468 and also in WO 97/12687 (particularly Figures 6a and 6b).
  • the nebulisers (devices) described therein are also known by the name Respimat ® .

Abstract

The present invention relates to the use of tiotropium salts in combination with salts of salmeterol for the manufacture of a medicament for the treatment of dyspnea.

Description

Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
The present invention relates to the use of tiotropium salts in combination with salts of salmeterol for the manufacture of a medicament for the treatment of dyspnea.
Medicament combinations based on anticholinergics and beta-2-agonists are known in the art. The combination of long acting anticholinergics with long acting beta-2- agonists is disclosed in WO00/69468. The specific combination of tiotropium salts with salts of salmeterol is also known from WO 02/38154 and WO 04/058233.
These protective rights do also disclose pharmaceutical compositions comprising salts of tiotropium and salts of salmeterol.
Surprisingly, it has been found that the combinations of tiotropium salts with salts of salmeterol are particularly useful in the preparation of a medicament for the treatment of dyspnea.
Dyspnea is a term known in the art. The term dyspnea is used to characterize a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social and environmental factors, and may induce secondary physiological and behavioural responses (see hereto: American Thoracic Society, Dyspnea: mechanisms, assessment, and management. A consensus statement, Am J Respir Crit care Med 159: 321 -340, 1999).
Therefore, the invention relates to the use of a tiotropium salt 1 together with a salmeterol salt 2 for the manufacture of a medicament for the treatment of dyspnea.
In another embodiment the invention relates to the use of a tiotropium salt 1 for the manufacture of a salmeterol salt 2 containing medicament for the treatment of dyspnea.
In a yet another preferred embodiment the invention relates use of a salmeterol salt 2 for the manufacture of a tiotropium salt 1. containing medicament for the treatment of dyspnea.
In another embodiment the invention relates to a method for the treatment of dyspnea, comprising the administration of a therapeutically effective amount of a tiotropium salt ± together with a therapeutically effective amount of a salmeterol salt 2 to a patient in need thereof. The term "therapeutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
The combined administration of a 1 and 2 may occur via a single active substance formulation but also via the successive administration of the two active substances in separate formulations. It is preferred according to the invention to administer the two active substance ingredients simultaneously in a single formulation.
The name tiotropium is intended to refer to the free cation (V) for the purposes of the present invention. The tiotropium salts 1 which may be used within the scope of the present invention include the compounds which contain, in addition to the cation tiotropium V_ an anion with a single negative charge, preferably an anion selected from among chloride, bromide, iodide, methanesulphonate and para- toluenesulphonate. Within the scope of the present invention, of all the tiotropium salts, the methanesulphonate, chloride, bromide or iodide are preferred, the methanesulphonate or bromide being of particular importance. Tiotropium bromide is of exceptional importance according to the invention.
By salts of salmeterol 2 are meant, according to the invention, pharmaceutically acceptable acid addition salts selected from among the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, xinafonic acid or maleic acid. According to the invention, the salmeterol salts 2 selected from among hydrochloride, hydrobromide, sulphate, phosphate and xinafoate are preferred. The salmeterol xinafoate salt 2 is particularly preferred.
In the combinations of active substances according to the invention consisting of 1 and 2 the ingredients 1 and 2 may be in the form of their enantiomers, mixtures of enantiomers or in the form of the racemates. The active substances 1 and 2 may optionally be in the form of the solvates or hydrates thereof.
Suitable inhalable preparations for the administration of 1 and 2 include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases. Inhalable powders according to the invention containing the active substance combination of 1 and 2 may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable adjuvants. The preparations may contain the active substance combination of Λ_ and 2 either together in one preparation or in two separate preparations.
The international patent applications WO00/69468, WO 02/38154 and WO 04/058233 which are hereby incorporated per reference in their entirety, disclose preferred pharmaceutical formulations and compositions that are also suitable for the use according to the invention.
The proportions in which the two active substances 1_ and 2 may be used in the combinations of active substances according to the invention are variable. The active substances ! and 2 may optionally be in the form of the solvates or hydrates thereof. Depending on the choice of the salts 1 or JJ1 the weight ratios which may be used for the purposes of the present invention vary on account of the different molecular weights of the various salt forms. Consequently, the weight ratios specified hereinafter are based on the tiotropium cation V and the free base of salmeterol 2[. The combinations of active substances according to the invention may contain V_ and 2^ in weight ratios in the range from 1 :300 to 30:1 , preferably from 1 :230 to 20:1 , particularly preferably from 1 : 150 to 10: 1 , more preferably from 1 :50 to 5: 1 , particularly preferably from 1 :35 to 2:1. Of particular interest according to the invention are pharmaceutical compositions containing the combination of V and 2| in a weight ratio in the range from 1 :25 to 1 :1 , preferably in the range from 1 :10 to 1 :2, particularly preferably in the range from 1 :5 to 1 :2.5.
For example, without restricting the scope of the invention, preferred combinations of 1 and 2 according to the invention may contain tiotropium V_ and salmeterol T_ in the following weight ratios: 1 :40; 1 :20; 1 :11.1 ; 1 :10; 1 :5.6; 1 :5; 1 :2.8; 1 :2.5; 1 :1.4; 1 :1.25; 1.44:1 , 1.6:1.
The pharmaceutical compositions according to the invention containing the combinations of Λ_ and 2 are normally used so that tiotropium V_ and salmeterol 2^ are administered together in doses of 0.01 to 10000 μg, preferably 0.1 to 2000 μg, particularly preferably from 1 to 1000 μg, more preferably from 5 to 500 μg, preferably, according to the invention, from 10 to 200 μg, preferably from 20 to 100μg, most preferably from 30 to 70 μg per single dose.
For example, combinations of Λ_ and 2 according to the invention contain an amount of tiotropium V and salmeterol 2^ such that the total dosage per single dose is 30μg, 35μg, 45μg, 55μg, 60μg, 65μg, 90μg, 105μg, 110μg, 110μg, 140μg or similar. In these dosage ranges the active substances V and 21 are present in the weight rations described hereinbefore.
For example, without restricting the scope of the invention, the combinations of 1 and 2 according to the invention may contain an amount of tiotropium V and salmeterol 2| such that 5μg of V and 25/vg of 21, 5/yg of Y_ and 50/yg of 21, 5//g of V and 10Oμg of 21, 5/yg of V_ and 200/yg of 21, 10/yg of V and 25μg of 21, 10/vg of V and 50/yg of 21, 10/yg of r and 10O/yg of 21, 10/yg of r and 200/yg of 21, 18/yg of V and 25/yg of 21, 18/yg of r and 50/yg of 21, 18/yg of V and 10O/yg of 21, 18/yg of V and 200/yg of 21, 20//g of H and 25/yg of 21, 20//g of V and 50/yg of 21, 20//g of V and 100//g of 21, 20/yg of V_ and 200/yg of 21, 36/yg of V and 25//g of 21, 36/yg of Y_ and 50/yg of 21, 36/yg of V and 10O/yg of 21, 36//g of V and 200/yg of 21, 40/yg of V and 25/yg of 21, 40/yg of V and 50/yg of 21, 40/yg of V_ and 100/yg of 21 or 40/yg of V_ and 200/yg of 21 are administered per single dose.
The combinations of active substances 1 and 2 according to the invention are preferably administered by inhalation. For this purpose, the ingredients 1 and 2 have to be incorporated in inhalable preparations.
Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases. Inhalable powders according to the invention containing the active substance combination of 1 and 2 may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable adjuvants. Within the scope of the present invention the term propellant- free solutions for inhalation also includes concentrates or sterile, ready-to-use solutions for inhalation. The preparations according to the invention may contain the active substance combination of 1 and 2 either together in one preparation or in two separate preparations. These preparations which may be used within the scope of the present invention are described in detail in the following section of the specification.
A) Inhalable powders containing the active substance combinations of 1 and 2 according to the invention :
The powders for inhalation according to the invention may contain 1 and 2 either on their own or in admixture with suitable physiologically harmless adjuvants.
If the active substances 1 and 2 are present in admixture with physiologically harmless adjuvants, the following physiologically harmless adjuvants may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these adjuvants with one another. Mono- or disaccharides are preferably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates, being preferred. The particularly preferred adjuvant according to the invention is lactose, most preferably lactose monohydrate.
Within the scope of the powders for inhalation according to the invention the adjuvants have a maximum mean particle size of up to 250μm, preferably between 10 and 150μm, particularly preferably between 15 and 80μm. If desired it may be useful to add finer adjuvant fractions having a mean particle size of 1 to 9μm to the abovementioned adjuvants. These latter finer adjuvants are also selected from the abovementioned group of adjuvants which may be used. Finally, in order to prepare the powders for inhalation according to the invention, micronised active substance 1. and 2, preferably having an average particle size of 0.5 to 10μm, particularly preferably from 1 to 6μm, is added to the adjuvant mixture. Processes for preparing the powders for inhalation according to the invention by grinding and micronising and finally mixing the ingredients together are known from the prior art. The powders for inhalation according to the invention may be prepared and administered either in the form of a single powder mixture which contains both Λ_ and 2 , or in the form of separate inhalable powders which contain only 1 and 2.
The inhalable powders according to the invention can be administered using inhalers known from the prior art.
Inhalable powders according to the invention which contain a physiologically harmless adjuvant in addition to 1 and 2 may for example be administered using inhalers which meter a single dose from a reservoir by means of a measuring chamber, as described in US 4570630A, or by other devices as described in DE 36 25 685 A. Preferably, the inhalable powders according to the invention which contain physiologically harmless adjuvant in addition to 1 and 2 are packed into capsules (to form so-called inhalettes), which are used in inhalers such as those described, for example, in WO 94/28958.
If the inhalable powders according to the invention are to be packed into capsules (inhalettes) as in the preferred application mentioned above, fillings of 1 to 30mg, preferably from 3 to 20mg, preferably 5 to 10 mg of inhalable powder per capsule are suggested. According to the invention, these contain the dosages specified above for V and T_ either together or separately per single dose. B) lnhalable aerosols containing propellant, comprising the active substance combinations of 1 and 2 according to the invention: lnhalable aerosols containing propellant according to the invention may contain 1 and 2 dissolved in the propellent gas or in dispersed form. 1 and 2 may be present in separate preparations or in a combined preparation, with Λ_ and 2 either both dissolved, both dispersed or only one component dissolved while the other is present in dispersed form.
The propellent gases which can be used to prepare the inhalable aerosols according to the invention are known from the prior art. Suitable propellent gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The abovementioned propellent gases may be used on their own or in mixtures thereof. Particularly preferred propellent gases are halogenated alkane derivatives selected from among TG11 , TG 12, TG 134a and TG227. Of the abovementioned halogenated hydrocarbons, TG134a (1 ,1 ,1 ,2-tetrafluoroethane) and TG227 (1 ,1 ,1 ,2,3,3,3- heptafluoropropane) and mixtures thereof are preferred according to the invention.
The propellant-gas-containing inhalable aerosols according to the invention may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
The propellant-gas-containing inhalable aerosols according to the invention may contain up to 5 % by weight of active substance 1 and/or 2. Aerosols according to the invention contain, for example, 0.002 to 5 % by weight , 0.01 to 3 % by weight , 0.015 to 2 % by weight , 0.1 to 2 % by weight , 0.5 to 2 % by weight or 0.5 to 1 % by weight of active substance Λ_ and/or 2.
If the active substances Λ_ and/or 2 are present in dispersed form the particles of active substance preferably have a mean particle size of up to 10 μm, preferably from 0.1 to 5 μm, particularly preferably from 1 to 5 μm.
The abovementioned propellant-gas-containing inhalable aerosols according to the invention can be administered by means of inhalers known in the art (MDIs = metered dose inhalers). Accordingly, a further aspect of the present invention relates to pharmaceutical compositions in the form of propellant-gas-containing aerosols as described above combined with one or more inhalers suitable for administering these aerosols. Furthermore, the present invention relates to inhalers, characterised in that they contain the propellant-gas-containing aerosols according to the invention as described above.
The present invention also relates to cartridges which are fitted with a suitable valve and can be used in a suitable inhaler and which contain one of the abovementioned propellant-gas-containing inhalable aerosols according to the invention. Suitable cartridges and methods of filling these cartridges with the propellant-gas-containing inhalable aerosols according to the invention are known from the prior art.
C) Propellant-free inhalable solutions containing the active substance combinations of 1 and 2 according to the invention:
It is particularly preferable for the active substance combination according to the invention to be administered in the form of propellant-free solutions for inhalation. Suitable solvents for this include aqueous or alcoholic, preferably ethanolic solutions. The solvent may be water on its own or a mixture of water and ethanol. The relative proportion of ethanol to water is not restricted, but the maximum limit is preferably up to 70 percent by volume, particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remaining percent by volume are made up with water. The preferred solvent is water without the addition of ethanol. The solutions containing 1 and 2 , separately or together, are adjusted to a pH of 2 to 7, preferably 2 to 5, particularly preferably 2.5 to 3.5, with suitable acids. Most preferably, inhalable solutions according to the invention which contain 1 and 2 together have a pH of about 2.9. This pH may be achieved using acids selected from among inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid and others. Preferred inorganic acids are hydrochloric acid and sulphuric acid. It is also possible to use the acids which are forming an acid addition salt with the active substance or, in the case of combined preparations, with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the abovementioned acids may also be used, particularly in the case of acids which have properties other than their acidifying properties, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH. According to the invention, there is no need to add editic acid (EDTA) or one of the known salts thereof, sodium edetate, to the present formulation as a stabiliser or complexing agent.
Other embodiments contains these compound(s).
In a preferred embodiment of this kind, the content based on sodium edetate is less than 100 mg / 100 ml, preferably less than 50 mg/100 ml, most preferably less than
20 mg/100 ml. lnhalable solutions in which the content of sodium edetate is 0 to 10mg/100ml are generally preferred.
Co-solvents and/or other adjuvants may be added to the propellant-free inhalable solutions according to the invention.
Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropylalcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
By excipients and additives is meant, in this context, any pharmacologically acceptable substance which is not an active substance, but can be formulated together with the active substance(s) in the pharmacologically suitable solvent, in order to improve the qualitative properties of the active substance formulation. Preferably, these substances do not have any appreciable pharmacological effects or at least have no undesirable effects in the context of the intended therapy. The excipients and additives include e.g. surfactants such as e.g. soya lecithin, oleic acid, sorbitan esters such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or extend the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art. The additives also include pharmacologically harmless salts such as sodium chloride, for example, as isotonic agents.
The preferred adjuvants include antioxidants, such as ascorbic acid, for example, unless it has already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins or provitamins occurring in the human body. Preservatives can be used to protect the formulation from contamination with pathogens. Suitable preservatives are those known from the prior art, particularly cetylpyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The abovementioned preservatives are preferably present in concentrations of up to 50mg/100ml, particularly between 5 and 20 mg/100ml. Preferred formulations contain only benzalkonium chloride and sodium edetate in addition to the solvent water and the active substance combination of 1 and 2. In another preferred embodiment, sodium edetate is omitted.
The propellant-free inhalable solutions according to the invention may be administered particularly using inhalers which are able to nebulise a small amount of a liquid formulation in the therapeutically necessary dose within a few seconds to form an aerosol suitable for therapeutic inhalation. Within the scope of the present invention, nebulisers are preferred in which a quantity of less than 100 μl_, preferably less than 50 μl_, particularly preferably between 20 and 30 μl_ of active substance solution can be nebulised, preferably in one operation, to produce an aerosol having an average particle size of less than 20 μm, preferably less than 10 μm, in such a way that the inhalable part of the aerosol corresponds to the therapeutically effective amount.
A device of this kind for the propellant-free administration of a metered amount of a liquid pharmaceutical composition for inhalation is described in detail, for example, in International Patent Application WO 91/14468 and also in WO 97/12687 (particularly Figures 6a and 6b). The nebulisers (devices) described therein are also known by the name Respimat®.

Claims

Patent Claims
1 ) Use of a tiotropium salt 1 together with a salmeterol salt 2 for the manufacture of a medicament for the treatment of dyspnea.
2) Use according to claim 1 , wherein the tiotropium salt I- is selected from the group consisting of chloride, bromide, iodide, methanesulphonate and para- toluenesulphonate.
3) Use according to claim 1 or 2, wherein the salt of salmeterol 2 is selected from among the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, xinafonic acid and maleic acid.
PCT/EP2006/064957 2005-08-06 2006-08-02 Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol WO2007017437A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008525547A JP2009504603A (en) 2005-08-06 2006-08-02 Method of treating dyspnea by administering a combination of tiotropium salt and salmeterol salt
CA002617897A CA2617897A1 (en) 2005-08-06 2006-08-02 Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
EP06792646A EP1959942A1 (en) 2005-08-06 2006-08-02 Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107267.6 2005-08-06
EP05107267 2005-08-06

Publications (1)

Publication Number Publication Date
WO2007017437A1 true WO2007017437A1 (en) 2007-02-15

Family

ID=37056590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064957 WO2007017437A1 (en) 2005-08-06 2006-08-02 Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol

Country Status (4)

Country Link
EP (1) EP1959942A1 (en)
JP (1) JP2009504603A (en)
CA (1) CA2617897A1 (en)
WO (1) WO2007017437A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
CN108451936A (en) * 2018-06-19 2018-08-28 杭州勃锐思莫生物医药科技有限责任公司 A kind of Tiotropium Bromide sucking preparation prepare treat lung-cancer medicament in apply

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038154A1 (en) * 2000-11-13 2002-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on tiotropium salts and on salmeterol salts
DE10145438A1 (en) * 2001-09-14 2003-04-03 Boehringer Ingelheim Pharma New salts of salmeterol with substituted salicylic acid, useful as well tolerated beta-mimetic agents for treating asthma or chronic obstructive pulmonary disease
DE10209243A1 (en) * 2002-03-04 2003-09-18 Boehringer Ingelheim Pharma Synergistic, well tolerated medicament combination of tiotropium salt and sparingly water-soluble salmeterol salt, useful for treating asthma or chronic obstructive pulmonary disease
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
MXPA04002401A (en) * 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Novel medicaments for inhalation.
DE10351663A1 (en) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
WO2002038154A1 (en) * 2000-11-13 2002-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on tiotropium salts and on salmeterol salts
DE10145438A1 (en) * 2001-09-14 2003-04-03 Boehringer Ingelheim Pharma New salts of salmeterol with substituted salicylic acid, useful as well tolerated beta-mimetic agents for treating asthma or chronic obstructive pulmonary disease
DE10209243A1 (en) * 2002-03-04 2003-09-18 Boehringer Ingelheim Pharma Synergistic, well tolerated medicament combination of tiotropium salt and sparingly water-soluble salmeterol salt, useful for treating asthma or chronic obstructive pulmonary disease
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAZZOLA, M. ET AL.: "The functional impact of adding salmeterol and tiotropium in patients with stable COPD", RESPIRATORY MEDICINE, vol. 98, 2004, pages 1214 - 1221, XP002402630 *
DONOHUE, J.F. ET AL.: "A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol", CHEST, vol. 122, 2002, pages 47 - 55, XP002402632 *
TASHKIN, D. & KESTEN, S.: "Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses", CHEST, vol. 123, no. 5, May 2003 (2003-05-01), pages 1441 - 1449, XP002402631 *
VAN NOORD, J.A. ET AL.: "Combination therapy of tiotropium plus salmeterol (T+S) superior to single agent therapy (Tio or Salm) in temis of dyspnea improvement in COPD", CHEST, vol. 128, no. 4suppl.s, 1 November 2005 (2005-11-01), pages 177S, XP009073611 *
VAN NOORD,J.A. ET AL.: "Improvement of dyspnea in COPD patients by combination therapy with tiotropium plus salmeterol (T+S) in responders as well as poor responders to salbutamol", CHEST, vol. 128, no. 4-suppl.s, 2 November 2005 (2005-11-02), pages 258S - 259S, XP009073612 *
WITEK JR, T.J. & MAHLER, D.A.: "Minimal important difference of the transition dyspnoea index in a multinational clinical trial", EUR RESPIR J, vol. 21, 2003, pages 267 - 272, XP002402633 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
CN108451936A (en) * 2018-06-19 2018-08-28 杭州勃锐思莫生物医药科技有限责任公司 A kind of Tiotropium Bromide sucking preparation prepare treat lung-cancer medicament in apply

Also Published As

Publication number Publication date
CA2617897A1 (en) 2007-02-15
JP2009504603A (en) 2009-02-05
EP1959942A1 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
AU2007202303B2 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
US20070128125A1 (en) Pharmaceutical Compositions Based on Tiotropium Salts and Salts of Salmeterol
AU775588B2 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1718336B1 (en) Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
CA2431565C (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
AU2003255289B2 (en) Inhalation medicaments containing a novel anticholinesterase drug in conjunction with corticosteroids and betamimetic drugs
US7332175B2 (en) Long-acting drug combinations for the treatment of respiratory complaints
CA2440699A1 (en) Compounds for treating inflammatory diseases
WO2019142214A1 (en) Pharmaceutical composition comprising tiotropium for inhalation
JP2009511541A (en) Novel pharmaceutical composition for the treatment of respiratory diseases
EP1651224B1 (en) Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20040048886A1 (en) Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists
NZ536284A (en) Medicaments containing steroids and a novel anticholinergic drug
EP1959942A1 (en) Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
CA2527178A1 (en) New long-acting drug combinations for the treatment of respiratory complaints
EP1651236A1 (en) Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
WO2012010854A1 (en) Inhalation formulations comprising carmoterol in combination with a corticosteroid
US20080031828A1 (en) Method for the Treatment of Dyspnea Comprising Combined Administration of Tiotropium Salts and Salts of Salmeterol
JP2010526763A (en) Novel long-acting pharmaceutical composition for the treatment of respiratory diseases
EP3525773A1 (en) Nebulizable compositions of tiotropium and formoterol
WO2004071384A2 (en) New pharmaceutical compositions based on anticholinergics and tace-inhibitors
WO2006087316A1 (en) Pharmaceutical compositions comprising anticholinergics and etiprednol
CA2515530A1 (en) New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2617897

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008525547

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006792646

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006792646

Country of ref document: EP